Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...

PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...

In trading on Monday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $11.8955 per share. By comparison ...

"This is a win for the research community," the company's the CEO says. The lawsuit against the company was filed in August 2022. Seattle-based Parse Biosciences secured another major legal ...